In breast cancer cell lines, melatonin strongly inhibits the phosphorylation of PI3K, AKT, PRAS40, and GSK-3 proteins, driving an inactivation of the PI3K/AKT signaling pathway. This evidence concerns the gene AKT1 and breast carcinoma.